Butterfly Medical raises $21m in funds for BPH device development

Butterfly Medical has raised $21m in Series C funding for the development and potential commercialisation of its minimally invasive device for BPH. The company has completed its pivotal clinical trial for the Butterfly prostatic retraction device. The CE Mark-approved device is intended to reduce symptoms associated with BPH. Credit: Butterfly Medical / PRNewswire. Butterfly Medical has raised $21m in Series C funding for the development and potential commercialisation of its minimally invasive device for benign prostatic hyperplasia (BPH). This latest funding round included participation from both new and existing investors, including MedVenture, Junson Capital, European Innovation Council (EIC), and New…

Source: Medical Device Network